Big Thank you THE LADY GARDEN FOUNDATION for supporting gynae cancers awareness and research- 10 fabulous years! I am proud of the team The Royal Marsden NHS Foundation Trust The ICR Happy International Women’s Day!

Join me Thursday 25 January 2024 in London RoySocMed to learn all the latest cutting-edge results setting new standards in endometrial cancer
rsm.ac.uk/events/oncolog…

An honour to deliver keynote lecture-ovarian cancer 3rd Indian Cancer Congress 2023 and be part of ISMPO ESMO - Eur. Oncology symposium- ‘genomics to the clinic’. Great networking at Indian Cancer Congress

⭐️ First of its kind ESMO - Eur. Oncology Resilience Task Force Special Session focusing on workforce sustainability in oncology. #ESMO23

The fully packed Hall Pamplona & discussions this morning prove that the issue is global 🌍. We as #OneOncologyCommunity need to take collective action!

Tisotumab Vedotin improves overall survival in recurrent/metastatic cervical cancer ESMO - Eur. Oncology Presidential. As ENGOTcx12 UK lead, thanks to all patients and trial teams globally-setting a new standard of care #ESMO2023 The Royal Marsden NHS Foundation Trust The ICR

Honoured to receive fellow ESMO - Eur. Oncology (FESMO) award #ESMO2023 Privileged to serve the global oncology community and our patients The Royal Marsden NHS Foundation Trust The ICR THE LADY GARDEN FOUNDATION Andres Cervantes

Thank you for congratulatory messages about Professorship The ICR The Royal Marsden NHS Foundation Trust An honour to be recognised for research and leadership-Thanks for believing in my potential, my team, friends, funders and patients ESMO - Eur. Oncology THE LADY GARDEN FOUNDATION

Practice-changing results: 1st phase 3 trial to show improvement in overall survival in platinum-resistant ovarian cancer (PROC). Mirvetuximab-setting a new standard of care for women with FR+ PROC. Thanks to all patients and researchers #ASCO23 The Royal Marsden NHS Foundation Trust NCRI Partnership

An honour to receive ⁦IJGC⁩ Award for the ATARI trial in clear cell and other rare Gynae cancers #IGCS2022 . Thank you all research teams and patients- working together delivering novel trials. ⁦ICR-CTSU⁩ ⁦⁦The Royal Marsden NHS Foundation Trust⁩

Delighted to co-chair ESMO - Eur. Oncology preceptorship Ovarian cancer with Isabelle Ray-Coquard. Great talks and networking with young oncologists and experts. Thank you for excellent clinical case discussions! See you at ESMO Gynae cancer Congress feb 2023!

Looking forward to discussing with you ideas to boost resilience and wellbeing in oncology. Join us tomorrow at 10am and help shape strategies for oncology professionals.

SOLO-1 7 year overall survival analysis-clinically meaningful improved OS with 2 years maintenance olaparib for women with newly diagnosed advanced BRCAm ovarian cancer. Thanks to patients and research teams #ESMO2022 The Royal Marsden NHS Foundation Trust The ICR

🗓️ Preparing your schedule for #ESMO22 ?

💥 Don't miss our Special Session on 'Wellbeing, burnout & resilience in oncology'!

Join us:
🎯 Explore key strategies & new initiatives for wellbeing
🎯 Hands-on coaching-style exercise to boost your personal wellbeing & resilience

#ESMOGynae2022 is underway live in Valencia and online! Delighted to be co-chairing ESMO Gynae cancer Congress with Dr Lorusso. Hear the latest treatment advances for women with Gynae cancers. ESMO - Eur. Oncology The Royal Marsden NHS Foundation Trust

#ESMOGynae22 : Susana Banerjee explains why attending this event ONSITE is crucial to meet colleagues, share experiences and discuss issues related to the field. Register by 25 May and save ➡️ ow.ly/OGGS50J16ie

#endometrialcancer #cervicalcancer #ovariancancer #gyncsm

Delighted! SOLO1 5 year follow up maintenance olaparib in newly-diagnosed #ovariancancer published today The Lancet Oncology Thanks to all patients, research teams and supporters - setting new standards of care. NCRI Partnership Ovacome - the ovarian cancer support charity The Royal Marsden NHS Foundation Trust The ICR

#ESGO2021 Tackling side effects of new cancer therapies- essential to give patients the best chance of continuing treatment. Delighted to be chairing and speaking live ESGO

Results in low grade serous ovarian cancer presented ESMO - Eur. Oncology Phase I FRAME trial @ICR: VS-6766 and defactinib- 64% response rate (KRAS mutated). Delighted to be Global lead of ongoing Phase II RAMP201 trial. Thanks to patients and trial teams @NCRI The Royal Marsden Cancer Charity @ovacome #ESMO21

Landmark phase III results ESMO - Eur. Oncology presidential symposium in cervical cancer- addition of pembrolizumab to platinum based chemotherapy + bevacizumab extends overall survival. Live Q&A shortly #ESMO21

youtube.com/watch?v=YvwcR3…
#ESMO21 LBA32 : EORTC 1508 study presented today by Susana Banerjee from @RoyalMarsdenNHS showing that Bev+Atezo improves time to subsequent therapy compared to Bev alone in #OvarianCancer . Analysis of the mandatory biopsies of key importance.